收藏切换
Systematic review and pharmacoeconomic evaluation of tirzepatide for the treatment of overweight/obesity
收藏切换
Hong-ye GENG, Li-xuan LI, Cheng-yuan LU, Shu-ling WANG*
Chinese Journal of New Drugs | 2026, 35(13) : 1447 - 1456
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(13): 1447-1456
Systematic review and pharmacoeconomic evaluation of tirzepatide for the treatment of overweight/obesity
Full
Hong-ye GENG, Li-xuan LI, Cheng-yuan LU, Shu-ling WANG*
Affiliations
  • School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China
Published: 2026-07-15 doi: 10.20251/j.cnki.1003-3734.2026.13.015
Outline
收藏切换
Objective:

To evaluate the efficacy, safety, and economics of tirzepatide in the treatment of overweight/obesity.

Methods:

A comprehensive comparison of the efficacy of tirzepatide and semaglutide in the treatment of overweight/obesity was performed using reticulated Meta-analysis (NMA), and cost-effectiveness analysis was used for pharmacoeconomic evaluation.

Results:

A total of 14 randomized controlled trials were searched. The NMA showed that for efficacy, the tirzepatide group was significantly better than the simelglutide group in terms of weight loss (MD=-6.50%, 95%CI: -8.13% to -4.87%), waist circumference reduction (MD=-5.40%), and the attainment rate of >15% weight loss (RR=1.28) (P<0.001), but the glycemic control was not statistically different. For safety, the overall incidence of gastrointestinal adverse events was similar in both groups, with a lower risk of vomiting with telbivudine (RR=0.70, 95%CI: 0.55~0.89). For the pharmacoeconomics, the ICER value of 87 714.55 yuan was well below the willingness-to-pay threshold, suggesting that tirzepatide was more cost-effective compared with semaglutide.

Conclusion:

The weight loss efficacy and economy of tirzepatide are significantly better than those of semaglutide, and its long-term safety needs to be further verified in the future.

obesity/overweight  /  tirzepatide  /  semaglutide  /  network Meta-analysis  /  systematic review  /  pharmacoeconomic evaluation
耿宏业, 李俐萱, 陆成远, 王淑玲. 替尔泊肽治疗超重/肥胖的系统评价与药物经济学分析. 中国新药杂志, 2026 , 35 (13) : 1447 -1456 . DOI: 10.20251/j.cnki.1003-3734.2026.13.015
Hong-ye GENG, Li-xuan LI, Cheng-yuan LU, Shu-ling WANG. Systematic review and pharmacoeconomic evaluation of tirzepatide for the treatment of overweight/obesity[J]. Chinese Journal of New Drugs, 2026 , 35 (13) : 1447 -1456 . DOI: 10.20251/j.cnki.1003-3734.2026.13.015
Year 2026 volume 35 Issue 13
60
11
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.13.015
  • Online Date:2026-10-26
  • Published:2026-07-15
Article Data
Affiliations
History
  • Accepted:2025-10-26
Funding
Affiliations
    School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.13.015
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT